CN105497334A - Chinese patent medicine for treating myasthenia gravis and preparation method thereof - Google Patents
Chinese patent medicine for treating myasthenia gravis and preparation method thereof Download PDFInfo
- Publication number
- CN105497334A CN105497334A CN201511012746.5A CN201511012746A CN105497334A CN 105497334 A CN105497334 A CN 105497334A CN 201511012746 A CN201511012746 A CN 201511012746A CN 105497334 A CN105497334 A CN 105497334A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese patent
- myasthenia gravis
- patent medicine
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses Chinese patent medicine for treating myasthenia gravis. The Chinese patent medicine is prepared from the following raw materials in parts by weight: 8-20 parts of typhae pollen, 5-14 parts of inula flower, 6-17 parts of halite, 5-17 parts of Szechuan lovage rhizome, 6-12 parts of saffron crocus, 7-18 parts of akebia stem, 5-12 parts of orange peel, 5-14 parts of prepared rehmannia rhizome, 5-12 parts of chicken gizzard membrane, 5-13 parts of twotooth achyranthes root, 5-10 parts of clematis root, 5-16 parts of flos magnolia, 5-10 parts of oryzanol, 4-15 parts of corydalis tuber and 5-10 parts of poria cocos. The Chinese patent medicine treats myasthenia gravis by clearing lung-heat, moistening dryness, invigorating qi, resolving phlegm, nourishing yin and promoting granulation, and a very good curative effect is achieved.
Description
Technical field
The present invention relates to a kind of Chinese patent medicine for myasthenia gravis and preparation method thereof, belong to tcm field.
Background technology
Myasthenia is the caused chronic disease of Phrenic nerve diaphragm obstacle.Clinical symptoms is that the skeletal muscle of getting involved is very easily tired, through having a rest and using anticholinergic medicine treatment rear section to recover.The generation of this disease and inherited genetic factors have certain relation, and any age all can fall ill, but the most common with 10 ~ 35 years old, also have above middle age patient.Myasthenia clinical manifestation is that whole body skeletal muscle all can be got involved, but it is the most common to get involved with extraocular muscles.Extraocular muscles is got involved and is embodied in blepharoptosis, diplopia etc., or whole-body muscle is got involved simultaneously, tired postemphasis, and rest rear section is recovered, heavy towards light sunset.The scope of muscle group of getting involved and degree variation very large.Patients serum's immunoglobulin of lab testing visible 2/3 increases.In the serum of Most patients, acetylcholinergic receptor (AchR) antibody increases.Caused by the myasthenia pathological changes that mainly postsynaptic membrane acetylcholinergic receptor (AChR) occurs.A lot of clinical picture also points out this sick relevant with disorder of immune mechanism.Myasthenia is the autoimmune disease that a kind of neuromuscular junction that affects the nerves transmits, its definite pathogeny is still indefinite at present, but about the research of this disease or a lot, wherein, most study be relation about myasthenia and thymus, and the effect of acetylcholine receptor antibodies in myasthenia, and large quantifier elimination finds, acetylcholinergic receptor (AchR) decreased number on myasthenia gravis patients neuromuscular junction postsynaptic membrane, there is anti-AchR antibody in acceptor site, and postsynaptic membrane has the deposition of IgG and C3 complex.And prove, the anti-AchR antibody in serum increase the minimizing with the effective AchR number caused by the deposition on postsynaptic membrane, be this pathogenetic main cause.And thymus is the main place that AchR antibody produces, therefore, the general and thymus of the generation of primary disease has close relationship.So, regulate human body AchR, make it increased number, dissolve the deposition on postsynaptic membrane, suppress the generation of anti-AchR antibody to be the key of curing primary disease.But above-mentioned therapy needs to use immunosuppressant, if with Chinese medicine in treatment, the side effect that immunosuppressant is brought can be reduced, the treatment of myasthenia gravis plays a part to escort, and can rebuild effect of autoimmune function.
Summary of the invention
For the deficiency that prior art exists, technical problem to be solved by this invention is, a kind of Chinese patent medicine for myasthenia gravis and preparation method thereof is provided, determined curative effect, comprehensively regulating, after treatment, not easily recurrence and cheap, has no side effect, can the amyasthenic medicine for the treatment of of long-term taking.
For solving the problems of the technologies described above, the technical scheme that the present invention takes is, for a Chinese patent medicine for myasthenia gravis, be made up of the raw material of following parts by weight: Pollen Typhae 8-20 part, Flos Inulae 5-14 part, halite 6-17 part, Rhizoma Chuanxiong 5-17 part, Stigma Croci 6-12 part, Caulis Akebiae 7-18 part, Pericarpium Citri Reticulatae charcoal 5-12 part, Radix Rehmanniae Preparata 5-14 part, Endothelium Corneum Gigeriae Galli 5-12 part, Radix Achyranthis 5-13 part, Radix Clematidis 5-10 part, Flos Magnoliae 5-16 part, oryzanol 5-10 part, Rhizoma Corydalis 4-15 part, Poria 5-10 part.
Optimize, the above-mentioned Chinese patent medicine for myasthenia gravis, is made up of the raw material of following parts by weight: Pollen Typhae 12-18 part, Flos Inulae 8-12 part, halite 10-12 part, Rhizoma Chuanxiong 8-13 part, Stigma Croci 8-10 part, Caulis Akebiae 10-13 part, Pericarpium Citri Reticulatae charcoal 7-10 part, Radix Rehmanniae Preparata 8-10 part, Endothelium Corneum Gigeriae Galli 6-9 part, Radix Achyranthis 7-9 part, Radix Clematidis 7-9 part, Flos Magnoliae 8-12 part, oryzanol 6-9 part, Rhizoma Corydalis 6-12 part, Poria 6-8 part.
Optimize, the above-mentioned Chinese patent medicine for myasthenia gravis, is characterized in that: be made up of the raw material of following parts by weight: Pollen Typhae 15 parts, Flos Inulae 10 parts, halite 11 parts, Rhizoma Chuanxiong 10 parts, Stigma Croci 9 parts, Caulis Akebiae 12 parts, Pericarpium Citri Reticulatae charcoal 9 parts, 9 parts, Radix Rehmanniae Preparata, Endothelium Corneum Gigeriae Galli 8 parts, Radix Achyranthis 8 parts, Radix Clematidis 8 parts, Flos Magnoliae 10 parts, oryzanol 8 parts, Rhizoma Corydalis 9 parts, 7 parts, Poria.
For a manufacture method for the Chinese patent medicine of myasthenia gravis, it is characterized in that: be made up of following steps:
(1) by Pollen Typhae, Flos Inulae, halite, Rhizoma Chuanxiong, Stigma Croci, Caulis Akebiae, Pericarpium Citri Reticulatae charcoal, Radix Rehmanniae Preparata, Endothelium Corneum Gigeriae Galli, Radix Achyranthis, Radix Clematidis, Flos Magnoliae, oryzanol, Rhizoma Corydalis, Poria grind into powder, stir;
(2) mixed-powder getting half step (1) puts into ethanol, soaks 30-60 hour;
(3) heated by the alcoholic solution that step (2) completes, heating steam condensation, lower than 80 degrees Celsius, is reclaimed by heating-up temperature;
(4) second half of the powder of step (1) is put into the pure water of 180 parts, heat 2.5 hours, take out medicine juice;
(5) condensed fluid that medicine juice step (4) completed and the middle condensation of step (3) are reclaimed mixes, and after mixing, low-temperature heat is to powdered;
(6) in powder is incapsulated.
Drug use result of the present invention shows there is following advantage: the present invention proposes employing and comprise multiple effective Chinese patent medicine new compositions and produce more favorably effect with synergism.
Myasthenia gravis is referred to as " myopathy " in the traditional Chinese medical science, and the cause of disease is mainly lung-heat Tianjin wound, damp and hot contamination, weakness of the spleen and stomach, caused by liver and kidney deficiency, blood deficiency and blood stasis.These pathogenesis are self-existent, be simultaneously again associated mutually, Chinese medical theory are done detailed dialectical, treat respectively simultaneously with rule for the treatment of guiding such as clearing away lung-heat and moistening for dryness, supplementing QI and nourishing YIN, granulation promotings of reducing phlegm.According to the dialectical analysis of the traditional Chinese medical science, the pathogeny and characteristics of myasthenia gravis is that lung spleen is suffered from a deficiency of the kidney, and causes collapse of QI, insufficiency of the spleen mistake fortune, and suffering from a deficiency of the kidney, it is solid to lose, and muscle arteries and veins muscle loses supports, visceral dysfunction, and atrophic debilities of the muscle is unable.Meanwhile, because lung spleen is suffered from a deficiency of the kidney, defend outer mistake solid, and endogenous damp formation causes diseases caused by exogenous pathogenic factor ailment said due to cold or exposure, internal injury phlegm-damp, inside and outside conjunction is attacked, and increases the weight of the state of an illness, therefore when focusing on evil (exopathogen, damp-phlegm), just (lung spleen kidney) during treatment, balance specimen.First eliminating pathogenic factor for supporting vital QI in treatment.The present invention, according to above-mentioned theory, is reduced phlegm mainly through clearing away lung-heat and moistening for dryness, QI invigorating, the means such as nourishing yin and promoting granulation is treated myasthenia gravis, and obtain good therapeutic effect.
Detailed description of the invention
embodiment 1
The present invention is a kind of Chinese patent medicine for myasthenia gravis, is made up of the raw material of following parts by weight: Pollen Typhae 8 parts, Flos Inulae 5 parts, halite 6 parts, Rhizoma Chuanxiong 5 parts, Stigma Croci 6 parts, Caulis Akebiae 7 parts, Pericarpium Citri Reticulatae charcoal 5 parts, 5 parts, Radix Rehmanniae Preparata, Endothelium Corneum Gigeriae Galli 5 parts, Radix Achyranthis 5 parts, Radix Clematidis 5 parts, Flos Magnoliae 5 parts, oryzanol 5 parts, Rhizoma Corydalis 4 parts, 5 parts, Poria.
For a manufacture method for the Chinese patent medicine of myasthenia gravis, it is characterized in that: be made up of following steps:
(1) by Pollen Typhae, Flos Inulae, halite, Rhizoma Chuanxiong, Stigma Croci, Caulis Akebiae, Pericarpium Citri Reticulatae charcoal, Radix Rehmanniae Preparata, Endothelium Corneum Gigeriae Galli, Radix Achyranthis, Radix Clematidis, Flos Magnoliae, oryzanol, Rhizoma Corydalis, Poria grind into powder, stir;
(2) mixed-powder getting half step (1) puts into ethanol, soaks 30 hours;
(3) heated by the alcoholic solution that step (2) completes, heating-up temperature is 75 degrees Celsius, heating steam condensation is reclaimed;
(4) second half of the powder of step (1) is put into the pure water of 180 parts, heat 2.5 hours, take out medicine juice;
(5) condensed fluid that medicine juice step (4) completed and the middle condensation of step (3) are reclaimed mixes, and after mixing, low-temperature heat is to powdered;
(6) in powder is incapsulated.
Medicine of the present invention is Chinese medicine capsule, sustained drug can be made to absorb, lasting medicine, and drug absorption is complete, comparatively fast plays curative effect.For showing that medicine of the present invention is to amyasthenic therapeutic effect, select meet the patient of inclusive criteria at the kind hospital outpatient in sea, Qingdao in May, 2009 ~ in March, 2014, totally 60 examples, adopt random digits table, by medical sequencing, at random patient is divided into two groups: treatment group 30 example, matched group 30 example, two groups of ratios are 1: 1.
The oral Chinese patent medicine of the present invention for the treatment of group, every day 3 times, takes before the meal half an hour by each two; The oral anticholinesterase of matched group and prednisone, every day 2 times, take before the meal half an hour by each 1.Two groups of courses for the treatment of are 4 weeks, all cases all carries out the conventional indexs such as the mensuration of electromyography and serum anti-acetic acid choline antibody and autoantibody after terminating with treatment when selected and detects, blepharoptosis, diplopia, stravismus before and after record patient treatment, the order of severity of histrionic muscles and the primary symptom such as masticatory muscles is unable and seizure frequency integration, carry out clinical symptoms therapeutic evaluation, quantize to mark to traditional Chinese medical science Syndrome Scale, compare the curative effect of two groups.
Therapeutic outcome:
Criterion of therapeutical effect is with reference to Chinese Medical Association's digestive endoscopy association Yantai meeting (2003) standard and national drug supervision
" new Chinese medicine guideline of clinical investigations " that management board (2002) formulates is formulated.
1. therapeutic effect of syndrome criterion
Cure: symptom, sign disappear or substantially disappear, syndrome integral reduces >=95%;
Effective: symptom, sign are obviously improved, syndrome integral reduces >=75%;
Effective: symptom, sign all take a favorable turn, syndrome integral reduces >=30%;
Invalid: symptom, sign are all not improved, even increase the weight of, syndrome integral is less than 30%.
Note: computing formula adopts nimodipine method: integration × 100% before (before treating the rear integration of integration-treatment)/treatment.
2. electromyography and serum anti-acetic acid choline antibody and autoantibody criterion of therapeutical effect
Cure: the mensuration reexamine focus of electromyography and serum anti-acetic acid choline antibody and autoantibody recovers normal (integration is 0 point);
Effective: the mensuration reexamine focus of electromyography and serum anti-acetic acid choline antibody and autoantibody is clearly better or improves (integration reduces 2 points);
Effective: the mensuration check pathological changes of electromyography and serum anti-acetic acid choline antibody and autoantibody takes a turn for the better to some extent or improves (integration reduces 1 point);
Invalid: the mensuration check pathological changes of electromyography and serum anti-acetic acid choline antibody and autoantibody does not take a turn for the better or increases the weight of (integration even increases without minimizing).
3. curative effect of disease standard
Cure: symptom, sign disappear or substantially disappear, the mensuration reexamine focus of electromyography and serum anti-acetic acid choline antibody and autoantibody recovers normal (integration is 0 point);
Effective: symptom, sign are clearly better, the mensuration reexamine focus of electromyography and serum anti-acetic acid choline antibody and autoantibody is clearly better or improves (integration reduces 2 points);
Effective: symptom, sign take a turn for the better to some extent, the mensuration check pathological changes of electromyography and serum anti-acetic acid choline antibody and autoantibody takes a turn for the better to some extent or improves (integration reduces 1 point);
Invalid: even symptom, sign all increase the weight of without improvement, the mensuration check pathological changes of electromyography and serum anti-acetic acid choline antibody and autoantibody does not take a turn for the better or increases the weight of (integration even increases without minimizing).
Chinese patent drugs for treatment myasthenia gravis clinical curative effect analysis of the present invention is as follows:
1. liang group tcm syndrome comparitive study is in table 1:
Table 1 liang group tcm syndrome comparitive study
| Group | N | Cure | Effective | Effectively | Invalid | Total effective rate (%) |
| Treatment group | 30 | 7 | 15 | 7 | 1 | 96.7 |
| Matched group | 30 | 2 | 8 | 6 | 14 | 53.3 |
Two groups of tcm syndrome curative effects are through inspection: two groups are being improved in tcm syndrome variant, and treatment group is better than matched group.Computational methods: (cure+effective+effectively)/N.
2. the mensuration integral contrast of liang rear electromyography of group treatment and serum anti-acetic acid choline antibody and autoantibody is in table 2:
The mensuration integral contrast (example) of electromyography and serum anti-acetic acid choline antibody and autoantibody after table 2 liang group treatment
| Group | N | 0 grade | I grade | II grade | III grade |
| Treatment group | 30 | 6 | 22 | 2 | 0 |
| Matched group | 30 | 2 | 20 | 5 | 3 |
Note: analyze through Ridit, the mensuration integral contrast of two groups of electromyographies and serum anti-acetic acid choline antibody and autoantibody after treatment, difference has significance, the mensuration integration improvement for the treatment of group electromyography and serum anti-acetic acid choline antibody and autoantibody is better than matched group, shows that the serum of Chinese patent medicine of the present invention to Patients With Myasthenia Gravis anti-acetic acid choline antibody and autoantibody improve and is better than anticholinesterase and prednisone.
3. after treatment, curative effect of disease compares in table 3:
Table 3 liang group Clinical efficacy comparison (example)
| Group | N | Cure | Effective | Effectively | Invalid | Total effective rate (%) |
| Treatment group | 30 | 7 | 15 | 7 | 1 | 96.7 |
| Matched group | 30 | 2 | 8 | 6 | 14 | 53.3 |
Analyze through Ridit, two groups of curative effect of disease comparing differences have significance, and treatment group is better than matched group.Computational methods: (cure+effective+effectively)/N.
Its overall clinical efficacy rate of Chinese patent drugs for treatment myasthenia gravis of the present invention is 96.7%, and it is 96.7% that tcm syndrome improves total effective rate; And matched group total effective rate is 53.3%, it is 53.3% that tcm syndrome improves total effective rate, and treatment group is improved total effective rate at overall clinical efficacy rate and sign and is obviously better than matched group.Illustrate that Chinese patent medicine of the present invention has clearing away lung-heat and moistening for dryness, QI invigorating is reduced phlegm, effect of nourishing yin and promoting granulation, therefore can be used for treating Patients With Myasthenia Gravis.
2. the measurement result of Chinese patent medicine clinical practice of the present invention to Patients With Myasthenia Gravis electromyography and serum anti-acetic acid choline antibody and autoantibody improves significantly, the mensuration comparing electromyography and serum anti-acetic acid choline antibody and autoantibody after treatment with matched group is improved and is obviously better than matched group, illustrates that Chinese patent medicine of the present invention significantly can improve Patients With Myasthenia Gravis.
3. Chinese patent medicine of the present invention is in clinical practice treatment myasthenia gravis process, and occur without any untoward reaction, safety is higher, is convenient to take, and patient is easy to accept, and compliance is good.
Conclusion: Chinese patent medicine of the present invention can reduce Patients With Myasthenia Gravis symptom integral, improves clinical symptoms, has obvious curative effects through statistical procedures; Clinical research does not find obvious adverse reaction and toxic and side effects, and safety is good.Be convenient to take, patient compliance is good, and total effective rate is better than matched group anticholinesterase and prednisone, and therapeutic effect is lasting.
embodiment 2
The present invention is a kind of Chinese patent medicine for myasthenia gravis, is made up of the raw material of following parts by weight: Pollen Typhae 20 parts, Flos Inulae 14 parts, halite 17 parts, Rhizoma Chuanxiong 17 parts, Stigma Croci 12 parts, Caulis Akebiae 18 parts, Pericarpium Citri Reticulatae charcoal 12 parts, 14 parts, Radix Rehmanniae Preparata, Endothelium Corneum Gigeriae Galli 12 parts, Radix Achyranthis 13 parts, Radix Clematidis 10 parts, Flos Magnoliae 16 parts, oryzanol 10 parts, Rhizoma Corydalis 15 parts, 10 parts, Poria.
For a manufacture method for the Chinese patent medicine of myasthenia gravis, it is characterized in that: be made up of following steps:
(1) by Pollen Typhae, Flos Inulae, halite, Rhizoma Chuanxiong, Stigma Croci, Caulis Akebiae, Pericarpium Citri Reticulatae charcoal, Radix Rehmanniae Preparata, Endothelium Corneum Gigeriae Galli, Radix Achyranthis, Radix Clematidis, Flos Magnoliae, oryzanol, Rhizoma Corydalis, Poria grind into powder, stir;
(2) mixed-powder getting half step (1) puts into ethanol, soaks 60 hours;
(3) heated by the alcoholic solution that step (2) completes, heating-up temperature is 78 degrees Celsius, heating steam condensation is reclaimed;
(4) second half of the powder of step (1) is put into the pure water of 180 parts, heat 2.5 hours, take out medicine juice;
(5) condensed fluid that medicine juice step (4) completed and the middle condensation of step (3) are reclaimed mixes, and after mixing, low-temperature heat is to powdered;
(6) in powder is incapsulated.
embodiment 3
The present invention is a kind of Chinese patent medicine for myasthenia gravis, is made up of the raw material of following parts by weight: Pollen Typhae 15 parts, Flos Inulae 10 parts, halite 11 parts, Rhizoma Chuanxiong 10 parts, Stigma Croci 9 parts, Caulis Akebiae 12 parts, Pericarpium Citri Reticulatae charcoal 9 parts, 9 parts, Radix Rehmanniae Preparata, Endothelium Corneum Gigeriae Galli 8 parts, Radix Achyranthis 8 parts, Radix Clematidis 8 parts, Flos Magnoliae 10 parts, oryzanol 8 parts, Rhizoma Corydalis 9 parts, 7 parts, Poria.
For a manufacture method for the Chinese patent medicine of myasthenia gravis, it is characterized in that: be made up of following steps:
(1) by Pollen Typhae, Flos Inulae, halite, Rhizoma Chuanxiong, Stigma Croci, Caulis Akebiae, Pericarpium Citri Reticulatae charcoal, Radix Rehmanniae Preparata, Endothelium Corneum Gigeriae Galli, Radix Achyranthis, Radix Clematidis, Flos Magnoliae, oryzanol, Rhizoma Corydalis, Poria grind into powder, stir;
(2) mixed-powder getting half step (1) puts into ethanol, soaks 48 hours;
(3) heated by the alcoholic solution that step (2) completes, heating-up temperature is 73 degrees Celsius, heating steam condensation is reclaimed;
(4) second half of the powder of step (1) is put into the pure water of 180 parts, heat 2.5 hours, take out medicine juice;
(5) condensed fluid that medicine juice step (4) completed and the middle condensation of step (3) are reclaimed mixes, and after mixing, low-temperature heat is to powdered;
(6) in powder is incapsulated.
Certainly, above-mentioned explanation is not limitation of the present invention, and the present invention is also not limited to above-mentioned citing; those skilled in the art; in essential scope of the present invention, the change made, remodeling, interpolation or replacement, all should belong to protection scope of the present invention.
Claims (4)
1. for a Chinese patent medicine for myasthenia gravis, it is characterized in that: be made up of the raw material of following parts by weight: Pollen Typhae 8-20 part, Flos Inulae 5-14 part, halite 6-17 part, Rhizoma Chuanxiong 5-17 part, Stigma Croci 6-12 part, Caulis Akebiae 7-18 part, Pericarpium Citri Reticulatae charcoal 5-12 part, Radix Rehmanniae Preparata 5-14 part, Endothelium Corneum Gigeriae Galli 5-12 part, Radix Achyranthis 5-13 part, Radix Clematidis 5-10 part, Flos Magnoliae 5-16 part, oryzanol 5-10 part, Rhizoma Corydalis 4-15 part, Poria 5-10 part.
2. the Chinese patent medicine for myasthenia gravis according to claim 1, is characterized in that: be made up of the raw material of following parts by weight: Pollen Typhae 12-18 part, Flos Inulae 8-12 part, halite 10-12 part, Rhizoma Chuanxiong 8-13 part, Stigma Croci 8-10 part, Caulis Akebiae 10-13 part, Pericarpium Citri Reticulatae charcoal 7-10 part, Radix Rehmanniae Preparata 8-10 part, Endothelium Corneum Gigeriae Galli 6-9 part, Radix Achyranthis 7-9 part, Radix Clematidis 7-9 part, Flos Magnoliae 8-12 part, oryzanol 6-9 part, Rhizoma Corydalis 6-12 part, Poria 6-8 part, Bulbus Lilii 5-7 part.
3. the Chinese patent medicine for myasthenia gravis according to claim 1, is characterized in that: be made up of the raw material of following parts by weight: Pollen Typhae 15 parts, Flos Inulae 10 parts, halite 11 parts, Rhizoma Chuanxiong 10 parts, Stigma Croci 9 parts, Caulis Akebiae 12 parts, Pericarpium Citri Reticulatae charcoal 9 parts, 9 parts, Radix Rehmanniae Preparata, Endothelium Corneum Gigeriae Galli 8 parts, Radix Achyranthis 8 parts, Radix Clematidis 8 parts, Flos Magnoliae 10 parts, oryzanol 8 parts, Rhizoma Corydalis 9 parts, 7 parts, Poria, Bulbus Lilii 6 parts.
4. the manufacture method of the Chinese patent medicine for myasthenia gravis of any one in claim 1-3, is characterized in that: be made up of following steps:
(1) by Pollen Typhae, Flos Inulae, halite, Rhizoma Chuanxiong, Stigma Croci, Caulis Akebiae, Pericarpium Citri Reticulatae charcoal, Radix Rehmanniae Preparata, Endothelium Corneum Gigeriae Galli, Radix Achyranthis, Radix Clematidis, Flos Magnoliae, oryzanol, Rhizoma Corydalis, Poria grind into powder, stir;
(2) mixed-powder getting half step (1) puts into ethanol, soaks 30-60 hour;
(3) heated by the alcoholic solution that step (2) completes, heating steam condensation, lower than 80 degrees Celsius, is reclaimed by heating-up temperature;
(4) second half of the powder of step (1) is put into the pure water of 180 parts, heat 2.5 hours, take out medicine juice;
(5) condensed fluid that medicine juice step (4) completed and the middle condensation of step (3) are reclaimed mixes, and after mixing, low-temperature heat is to powdered;
(6) in powder is incapsulated.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511012746.5A CN105497334A (en) | 2015-12-31 | 2015-12-31 | Chinese patent medicine for treating myasthenia gravis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511012746.5A CN105497334A (en) | 2015-12-31 | 2015-12-31 | Chinese patent medicine for treating myasthenia gravis and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105497334A true CN105497334A (en) | 2016-04-20 |
Family
ID=55705893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201511012746.5A Withdrawn CN105497334A (en) | 2015-12-31 | 2015-12-31 | Chinese patent medicine for treating myasthenia gravis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105497334A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102406798A (en) * | 2011-11-27 | 2012-04-11 | 鲍颖 | Chinese medicinal composition for treating myasthenia gravis |
| CN102526389A (en) * | 2012-03-09 | 2012-07-04 | 王利伟 | Traditional Chinese medicine for treating myasthenia gravis and amyotrophy |
| CN104147455A (en) * | 2014-08-27 | 2014-11-19 | 中南林业科技大学 | Preparation for treating ocular myasthenia gravis |
| CN104721515A (en) * | 2013-12-19 | 2015-06-24 | 曲凤至 | Effective myasthenia gravis recovery preparation |
-
2015
- 2015-12-31 CN CN201511012746.5A patent/CN105497334A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102406798A (en) * | 2011-11-27 | 2012-04-11 | 鲍颖 | Chinese medicinal composition for treating myasthenia gravis |
| CN102526389A (en) * | 2012-03-09 | 2012-07-04 | 王利伟 | Traditional Chinese medicine for treating myasthenia gravis and amyotrophy |
| CN104721515A (en) * | 2013-12-19 | 2015-06-24 | 曲凤至 | Effective myasthenia gravis recovery preparation |
| CN104147455A (en) * | 2014-08-27 | 2014-11-19 | 中南林业科技大学 | Preparation for treating ocular myasthenia gravis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jie et al. | Kuijieling decoction suppresses NLRP3-Mediated pyroptosis to alleviate inflammation and experimental colitis in vivo and in vitro | |
| Lang et al. | Research progress in the treatment of idiopathic membranous nephropathy using traditional Chinese medicine | |
| Xi et al. | Free Wanderer Powder regulates AMPA receptor homeostasis in chronic restraint stress-induced rat model of depression with liver-depression and spleen-deficiency syndrome | |
| CN103845429A (en) | Traditional Chinese medicine for treating chronic hepatitis | |
| CN105497334A (en) | Chinese patent medicine for treating myasthenia gravis and preparation method thereof | |
| CN105796654A (en) | Traditional Chinese medicine composition for treating diarrhea irritable bowel syndrome, navel paste and application | |
| CN103705632B (en) | The application of BUPIXIAO PIAN in preparation treatment penile induration disease drug | |
| CN105456941A (en) | Chinese patent medicine for treating myasthenia gravis and preparation method of Chinese patent medicine | |
| CN104784522A (en) | Chinese patent medicine for treating myasthenia gravis and preparation method of Chinese patent medicine | |
| CN101693084B (en) | Medical composition for treating epigastric pain yin deficiency syndrome and preparation method thereof | |
| CN103893582A (en) | Traditional Chinese medicament for treating acne rosacea | |
| Lee et al. | Herbal medicine and acupuncture combined treatment attenuates colitis in rats | |
| CN108295168B (en) | Traditional Chinese medicine composition for treating post-stroke depression | |
| CN105106337A (en) | Thunder god vine medical wine for treating rheumatoid arthritis | |
| CN107320662B (en) | Traditional Chinese medicine composition for treating nasopharyngeal carcinoma and cooperating with nasopharyngeal carcinoma chemoradiotherapy | |
| Yang et al. | Studying the nature of ascending-descending-floating-sinking of Chinese medicines based on gonadotropin-releasing hormone | |
| CN110742935A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating chronic alcoholic steatohepatitis | |
| CN104524085A (en) | Drug for treatment of primary dysmenorrhea | |
| CN104069227A (en) | Traditional Chinese medicine for treating coughing, phlegm, and asthma | |
| CN103393909A (en) | Chinese medicinal preparation for treating biliary calculus with cholecystitis | |
| CN103860786A (en) | Medicine for treating puerperal fever | |
| CN103110853A (en) | Chinese herba preparation for treating nephrotic syndrome | |
| CN114869956B (en) | Pharmaceutical composition for treating post-stroke dyskinesia, and preparation method and application thereof | |
| CN102641350A (en) | Lung-warming panting-calming granule and preparation process thereof | |
| CN114588242B (en) | Pharmaceutical composition for treating rheumatoid arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160420 |
|
| WW01 | Invention patent application withdrawn after publication |